Peutz-Jeghers Syndrome: Cancer Surveillance and Polyp Management
Patients with Peutz-Jeghers syndrome require comprehensive, age-stratified surveillance beginning in childhood with baseline upper endoscopy and small bowel imaging at age 8, followed by multi-organ cancer screening starting at age 18-25 depending on the organ system, with polypectomy recommended for all polyps >1 cm to prevent both malignant transformation and life-threatening complications like intussusception.
Polyp Management Strategy
Remove all gastrointestinal polyps ≥10-15 mm during surveillance endoscopy to prevent intussusception and potential malignant transformation 1. The rationale is compelling:
- Intussusception risk reaches 50% by age 20 years, with 95% occurring in the small intestine 2
- Intussusceptions are caused by polyps with median size of 35 mm (range 15-60 mm), and 92.5% require surgical intervention 2
- 36.4% of pediatric patients have polyps >15 mm before age 8, necessitating early surveillance 3
- Endoscopic ischemic polypectomy shows superior safety compared to conventional polypectomy (0.28% vs 2.83% complication rate, p=0.042) 3
Age-Stratified Surveillance Protocol
Birth to Age 12 (Males and Females)
- Annual physical examination focusing on testicular examination and signs of precocious puberty 1, 4
- Optional: Testicular ultrasound every 2 years until age 12 (Sertoli cell tumor risk is 9%) 1, 4
Age 8: Baseline GI Evaluation
- Upper endoscopy and small bowel imaging (video capsule endoscopy or CT/MRI enterography preferred to minimize radiation) 1, 4
- If polyps found: repeat every 2-3 years with polypectomy 1, 4
- If negative: resume at age 18 4
Age 18: Comprehensive GI Surveillance Begins
- Colonoscopy every 2-3 years (lifetime colorectal cancer risk 39%) 1, 4
- Upper endoscopy every 2-3 years (gastric cancer risk 29%) 1, 4
- Small bowel visualization every 2-3 years (small intestinal cancer risk 13%) 1, 4
Critical caveat: Shorter intervals may be necessary based on polyp size, number, and pathology 4. The majority of colorectal cancers occur after age 27, but cases have been reported in teenage years 1.
Age 21 (Females Only)
- Annual pelvic examination with Pap smear (cervical adenocarcinoma risk ≥10%, particularly minimal deviation adenocarcinoma) 1, 4
Age 25-30: Expanded Cancer Surveillance
For all patients:
- Pancreatic surveillance starting age 25-30 with endoscopic ultrasound (EUS) every 1-2 years OR MRI/MRCP annually 1, 4
- Pancreatic cancer lifetime risk is 11-36%, with PJS being the strongest known risk factor except hereditary pancreatitis 1, 4
- EUS is preferred modality with highest sensitivity for early pancreatic cancer detection 1
- 95% of pancreatic cancers occur after age 24 1
- CT scan and CA19-9 offered as options but not established as effective screening 1
For females:
Breast surveillance starting age 25-30 1, 4:
- Monthly breast self-examination starting age 18 1
- Clinical breast examination every 6-12 months starting age 25 1, 4
- Annual mammography starting age 25 (or earlier based on family history) 1, 4
- Annual breast MRI as alternative or adjunct 1, 4
- Lifetime breast cancer risk 32-54%, comparable to BRCA1/2 mutation carriers 1, 4
Gynecologic surveillance starting age 25 1:
Key Clinical Pitfalls to Avoid
Do not delay small bowel surveillance until age 18 in symptomatic children - 68.2% of pediatric PJS patients experience intussusception before their first double-balloon enteroscopy 3. Early baseline evaluation at age 8 is critical 1, 4.
Do not rely solely on scheduled surveillance for cancer detection - in a Danish nationwide study, 92% of cancers were identified between scheduled examinations 5. Maintain high clinical suspicion for interval symptoms.
Do not use CA19-9 as primary pancreatic screening tool - its usefulness as a screening test has not been established 1. EUS or MRI/MRCP are preferred modalities 4.
Do not assume genetic testing negativity excludes PJS - 10-15% of patients meeting clinical criteria have no identifiable STK11 pathogenic variant, including 6% with mosaicism 5, 6. These patients still require full surveillance 1.
Mortality and Quality of Life Considerations
At age 40, the probability of cancer is 21% and death is 16%; by age 70, these rise to 71% and 69% respectively 5. This underscores the critical importance of lifelong surveillance.
The lifetime risk for any cancer ranges from 37-93%, with relative risks 9.9-18 times higher than the general population 7. Average age of cancer diagnosis is 42 years, but malignancies occur throughout life starting in childhood 7.
Prophylactic surgery considerations: For women, prophylactic mastectomy may be discussed on a case-by-case basis given the 32-54% breast cancer risk 1. Total hysterectomy should be considered after childbearing given the ≥10% cervical adenocarcinoma risk 4.